Fig. 6.

ISD017 inhibits ISG responses in lupus patient cells. (a) Serum from 164 lupus patients and 21 healthy controls was analyzed for levels of IFN-I bioactivity. The data are presented as levels from individual donors. (b) Illustration of experimental set-up for the analysis of the effect of ISD017 on cytokine expression by PBMCs from lupus patients. (c) PBMCs from eleven IFN-I^high lupus patients were cultured for 16 h in the presence or absence of ISD017 (200 µg/ml). Supernatants were isolated and analyzed for the levels of CXCL10. (d) The same supernatants as in panel c were analyzed for CCL19. (e) Illustration of experimental set-up for analysis of the effect of ISD017 on Extracellular vesicle (EV)-induced cytokine expression in PBMCs from healthy donors. (f) PBMCs from a healthy donor were treated for 16 h with EVs isolated from seven IFN-I^high lupus patients in the presence or absence of ISD017 (200 µg/ml). Supernatants were isolated and analyzed for the levels of CXCL10. The data in panel a are presented as mean levels from individual donors. The data in panel c, d, and f are presented as matched values from cultures from individual patient PBMCs in the absence (blue) or presence (red) of ISD017. [Statistical analysis of the data in c, d, f i were performed using two-tailed one-way ANOVA test].